Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Apr;37(2):120-124.
doi: 10.3393/ac.2019.08.17. Epub 2020 Mar 16.

An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient

In-Gyu Song  1 , Kyung Uk Jung  1 , Hyung Ook Kim  1 , Hungdai Kim  1 , Ho-Kyung Chun  1
Affiliations
Case Reports

An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient

In-Gyu Song et al. Ann Coloproctol. 2021 Apr.

Abstract

Everolimus (Afinitor) is an inhibitor of mammalian target of rapamycin. Polmacoxib (Acelex) is a nonsteroidal anti-inflammatory drug that belongs to the cyclooxygenase-2 (COX-2) inhibitor family and is mainly used for treatment of arthritis. Intestinal perforation has not been reported previously as a complication of everolimus, and perforation of the lower intestinal tract caused by a selective COX-2 inhibitor is extremely rare. We present here a case of colon perforation that occurred after use of polmacoxib in a metastatic breast cancer patient who had been treated with everolimus for the preceding six months.

Keywords: Colon perforation; Everolimus; Polmacoxib, Nonsteroidal anti-inflammatory agents; mTOR inhibitor.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.
Fig. 1.
Abdominopelvic computed tomography scan showed multiple wall defects of the descending colon with perilesional fat infiltration (A, yellow arrow) and pneumoperitoneum (B, perihapatic free air), suggesting multiple perforations of the descending colon.
Fig. 2.
Fig. 2.
Multiple ulcerations (yellow circles) in the delivered specimen.
Fig. 3.
Fig. 3.
Pathologic evaluation of the specimen using H&E stain, showing chronic active transmural inflammation (A, B, D), vascular congestion (C), and acute serositis (A).
Fig. 4.
Fig. 4.
Emergency sigmoidoscopy showed multiple geographic ulcers (A) in the remnant colonic wall (B).
Fig. 5.
Fig. 5.
Ulcerations of the colon wall self-resolved, and remnant colonic mucosa was normal in colonoscopy 6 months after surgery. (A) Sigmoid colon which was severely ulcerated in the past, (B) anastomosis site.
See this image and copyright information in PMC

References

    1. Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med. 2012;366:520–9. - PMC - PubMed
    1. Paplomata E, Zelnak A, O’Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat. 2013;140:453–62. - PubMed
    1. Lee M, Yoo J, Kim JG, Kyung HS, Bin SI, Kang SB, et al. A randomized, multicenter, phase III trial to evaluate the efficacy and safety of polmacoxib compared with celecoxib and placebo for patients with osteoarthritis. Clin Orthop Surg. 2017;9:439–57. - PMC - PubMed
    1. Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol. 2014;25:763–73. - PubMed
    1. Mychaluk J, Piprot C, Sevestre H, Merviel P, Gondry J, Fauvet R. Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer. Presse Med. 2009;38:1370–4. - PubMed

Publication types

LinkOut - more resources